title: New pharmacological treatment options for irritable bowel syndrome with constipation.
abstract: BACKGROUND
  Constipation predominant irritable bowel syndrome (IBS-C) is a common disorder and accounts for a large number of ambulatory visits. Sensory abnormalities, that is, presence of abdominal pain and discomfort, distinguish IBS-C from chronic idiopathic constipation.
  
  
  METHODS
  This review focuses on the pharmacology, efficacy, safety, and future of prucalopride, YKP-10811, DSP-6952, dexloxiglumide, linaclotide, plecanatide, tenapanor, and elobixibat.
  
  
  CONCLUSIONS
  It is now well established that treatment focusing only on bowel transit provides incomplete relief to patients with IBS-C. Improved understanding of pathophysiology of IBS-C has led to use of sensory end points like complete spontaneous bowel movements and the FDA combined end point (abdominal pain and complete spontaneous bowel movements) in clinical trials. A number of drugs are in development and provide hope for this challenging group of patients. However, because of recent failures secondary to ineffectiveness and/or adverse events, we cautiously await how clinical data play out in larger studies and in clinical practice.
authors.affiliation: a Section of Digestive Diseases and Nutrition, Department of Medicine , Oklahoma University School of Medicine , 920 Stanton L. Young Blvd. WP 1345, Oklahoma City , OK 73104 , USA.
authors.forename: Salman
authors.initials: S
authors.lastname: Nusrat
authors.affiliation: a Section of Digestive Diseases and Nutrition, Department of Medicine , Oklahoma University School of Medicine , 920 Stanton L. Young Blvd. WP 1345, Oklahoma City , OK 73104 , USA.
authors.forename: Philip B
authors.initials: PB
authors.lastname: Miner
mesh_terms: D015746:Abdominal Pain / Q000209:etiology; D000818:Animals; D003248:Constipation / Q000188:drug therapy* / Q000209:etiology; D015195:Drug Design; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D005765:Gastrointestinal Agents
keywords: DSP-6952; YKP-10811; bile acid transport inhibitor; cholecystokinin receptor antagonist; dexloxiglumide; elobixibat; guanylate cyclase-C agonist; linaclotide; plecanatide; serotonin agonist; sodium–proton exchange inhibitor; tenapanor